Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000555429 | SCV000653564 | uncertain significance | Dyskeratosis congenita, autosomal recessive 5; Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3 | 2021-09-06 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine with glutamic acid at codon 552 of the RTEL1 protein (p.Ala552Glu). The alanine residue is moderately conserved and there is a moderate physicochemical difference between alanine and glutamic acid. This variant is present in population databases (rs760398738, ExAC 0.02%). This variant has not been reported in the literature in individuals affected with RTEL1-related conditions. ClinVar contains an entry for this variant (Variation ID: 473906). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001764606 | SCV002000951 | uncertain significance | not provided | 2020-04-21 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Mayo Clinic Laboratories, |
RCV001764606 | SCV004225519 | uncertain significance | not provided | 2023-02-15 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001834807 | SCV002095424 | uncertain significance | Dyskeratosis congenita | 2020-08-24 | no assertion criteria provided | clinical testing |